Trader consensus heavily favors no new pandemic emerging in 2026 at 95% implied probability, driven by persistently low global respiratory virus activity through early October, with influenza and SARS-CoV-2 positivity remaining below 10% in most regions per WHO surveillance. Localized outbreaks, including the largest recorded Bundibugyo Ebola event in the Democratic Republic of the Congo with over 8,700 confirmed cases and 4,200 deaths, plus imported detections elsewhere, have not produced sustained international human-to-human transmission. Measles and other vaccine-preventable diseases show regional increases but lack the characteristics of a novel pandemic pathogen. Realistic challenges include undetected zoonotic spillover or rapid adaptation of avian influenza strains like H5N1 enabling efficient airborne spread, underscoring the value of ongoing genomic surveillance by agencies such as the CDC and WHO.